OUR PRODUCTS

Our Pipeline

We challenge ourselves to rethink the way medicines are developed,
and are investing now to bring more value to patients in the future.

We strive for constant innovation and we are putting our passion and expertise to work in new areas including gastroenterology and endocrinology.

SB16

Biosimilar candidate

  • Molecule Denosumab
  • Reference Biologic Proliai
  • Therapeutic Area Endocrinology
SB17

Biosimilar candidate

  • Molecule Ustekinumab
  • Reference Biologic Stelaraii
  • Therapeutic Area immunology
SB26

Novel biologic

  • Molecule Ulinastatin-Fc
    Fusion Protein
  • Therapeutic Area Gastroenterology
SB27

Biosimilar candidate

  • Molecule Pembrolizumab
    Keytrudaiii
  • Therapeutic Area Oncology

*Pipeline last updated Feb 2024

  • iProlia is a registered trademark of Amgen
  • iiStelara is a registered trademark of Janssen
  • iii

    Keytruda is a registered trademark of Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, known as MSD outside the United States and Canada.

SAMSUNG BIOEPIS

확인 취소
레이어 팝업 닫기